UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------
FORM 8-K
-----------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 2, 2007
Date of Report (Date of earliest event reported)
-----------------
PRO-PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
-----------------
NEVADA 000-32877 04-3562325
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
7 WELLS AVENUE
NEWTON, MASSACHUSETTS
02459
(Address of Principal Executive Offices) (Zip Code)
(617) 559-0033
(Registrant's telephone number, including area code)
-----------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Other Events
Item 8.01 Other Events.
On August 3, 2007, Pro-Pharmaceuticals, Inc. announced it has retained Camargo
Pharmaceutical Services, LLC to provide strategic regulatory support for the
Company's 505(b)(2) filings. A copy of the news release is furnished as Exhibit
99.1 to this report and is incorporated herein by reference. This information
shall not be deemed to be "filed" for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, and shall not be deemed to be
incorporated by reference in any filing under the Securities Act of 1933, as
amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) The following exhibit is furnished with this report:
Exhibit Number 99.1
Description
News release dated August 3, 2007 announcing Pro-Pharmaceuticals, Inc. has
retained Camargo Pharmaceutical Services, LLC to provide strategic regulatory
support for the Company's 505(b)(2) filings.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PRO-PHARMACEUTICALS, INC.
By: /s/ David Platt
-------------------------------
David Platt
Chief Executive Officer
Date: August 3, 2007
EXHIBIT INDEX
Exhibit
Number Exhibit
------- ---------------------------------------------------------------------
99.1 News release dated August 3, 2007, reporting a consulting agreement.